In the News

LACRIFILL^® Canalicular Gel is changing clinical practice and changing lives when it comes to dry eye treatment.

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Continues Its Introduction of LACRIFILL^® Canalicular Gel, a Novel Therapy for Dry Eye, During American Academy of Ophthalmology (AAO) 2024

10/17/24

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. in April and will continue its introduction to leading ophthalmologists during AAO 2024. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL^® Canalicular Gel, a Novel Therapy for Dry Eye

05/29/24

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL^® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting

04/02/24

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Appoints Renowned Oculoplastic Surgeon, John P. Fezza, MD to Its Medical Advisory Board

03/14/24

« Older Entries

Next Entries »



Come meet with us at these 2026 Meetings and Conferences

ASCRS
April 10–13
Washington D.C.

Vision Source Exchange
April 29–May 2
Nashville, TN

AAO
October 10–12
New Orleans, LA

In the News

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Continues Its Introduction of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, During American Academy of Ophthalmology (AAO) 2024

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Appoints Renowned Oculoplastic Surgeon, John P. Fezza, MD to Its Medical Advisory Board

Come meet with us at these 2026 Meetings and Conferences

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Continues Its Introduction of LACRIFILL^® Canalicular Gel, a Novel Therapy for Dry Eye, During American Academy of Ophthalmology (AAO) 2024

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL^® Canalicular Gel, a Novel Therapy for Dry Eye

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL^® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting